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Background: Multiple sclerosis (MS) is an autoimmune disorder of the CNS in which
inflammation, demyelination, and axonal damage of the central nervous system coexist.
Fatigue is one of the most disabling symptoms in MS and little is known about the
neurophysiological mechanisms involved.
Methods: To give more mechanistic insight of fatigue in MS, we studied a cohort
of 17MS patients and a group of 16 age-matched healthy controls. Baseline Fatigue
Severity Scales and Fatigue Rating were obtained from both groups to check the level
of fatigue and to perform statistical correlations with fatigue-induced neurophysiologic
changes. To induce fatigue we used a handgrip task. During the fatiguing task, we
evaluated fatigue state (using a dynamometer) and after the task we evaluated the Borg
Rating of Perceived Exertion Scale. Transcranial magnetic stimulation and peripheral
electric stimulation were used to assess corticospinal tract and peripheral system
functions before and after the task.
Results: Clinically significant fatigue and central motor conduction time were greater
in patients than in controls, while motor cortex excitability was decreased and maximal
handgrip strength reduced in patients. Interestingly, fatigue state was positively correlated
to perceived fatigue in controls but not in patients. Furthermore, in the presence of similar
fatigue state over time, controls showed a significant fatigue-related reduction in motor
evoked potential (a putative marker of central fatigue) whereas this effect was not seen
in patients.
Conclusions: in MS patients the pathogenesis of fatigue seems not driven by
the mechanisms directly related to corticospinal function (that characterize fatigue in
controls) but seems probably due to other “central abnormalities” upstream to primary
motor cortex.
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INTRODUCTION
Multiple sclerosis (MS) is an immuno-mediated disorder of
the central nervous system (CNS) in which inflammation,
demyelination, and axonal damage coexist (1). MS prevalence
and incidence have increased progressively over time (2).
Importantly, MS is commonly diagnosed between 20 and 40
years of age, affecting the early stages of working lives and
leading to a further increase in social costs (3, 4). MS is
characterized by sensory and motor symptoms, bladder and
bowel problems, cognitive impairment and fatigue. Fatigue trait
in MS was defined, by the Multiple sclerosis council for clinical
practice guidelines, as “a subjective lack of physical and/or
mental energy that is perceived by the individual or caregiver to
interfere with usual and desired activities”(5). It occurs frequently
and is considered one of the most disabling symptom since it
interferes with the performance of daily activities (6). However,
the pathophysiology of fatigue and the mechanisms involved are
still poorly understood (7–13).
On the other hand, fatigue state, can be defined as the
decline in peak force (torque) after performing an exercise
intervention (14). Generally, fatigue triggered by overstrain in
healthy subjects, is mediated by muscular factors even if changes
in the peripheral and central nervous system as well as lack of
self-motivation (15) or a subjective decrease in mental/physical
energy (16) are also involved (7, 17–19).
In this line, in healthy subjects it was demonstrated that the
development of fatigue depends on the changes affecting several
structures such as spinal cord, cerebral cortex and subcortical
structures (17, 20, 21). Accordingly, it was recently shown that
fatigue in MS patients depends on the changes of functionality
of CNS (10, 11, 21–26)]. Since the impact of fatigue in daily life
of MS patients is high and since 80–90% of MS patients present
with fatigue (26), a more profound knowledge of the mechanisms
involved in the fatigue development could help to better evaluate
patients and ultimately could help to find new treatments.
Although several works seem to suggest that MS fatigue is
associated to corticospinal dysfunction, other works did not
confirm this causal link (10, 21, 23). Moreover, in healthy subjects
not-fatiguing tasks did not lead to reduction in Motor Evoked
Potentials (MEP) (i.e., post exercise depression) (27), while
studies evaluating post-exercise depression of MEP amplitude
in MS patients demonstrated variable results (increased in one
study, reduced in another and similar to healthy subjects in 3
studies) and that the amount of post-exercise depression was not
related to self-reported fatigue in MS (28).
In the present study, we aimed to give more mechanistic
insights about the lack of post exercise depression in fatigued
MS patients, by studying the effects of a fatiguing hand
task on motor cortex and peripheral nerve functions and
by looking for any correlation between neurophysiological
parameters of central and peripheral fatigue, maximal handgrip
strength (MHS) and subjective perception of fatigue. We
hypothesized that the lack of post exercise depression
in fatigued MS patients could be explained by different




We enrolled 17 consecutive MS patients (4 males) and 16
healthy controls (8 males). The study protocol was approved
by the Ethical Committee for Clinical Research (Toledo) and
was performed according to the Declaration of Helsinki. All
participants gave written informed consent prior to participation.
Patients and controls were asked to quantify their weekly physical
activity referring to recreational activity: they were asked for
how many days a week and for how many hours a day they
perform vigorous recreational activity (such as sport, fitness and
other aerobic sports). Subjects that did not perform at least
3 h /week did not enter the study. All controls and patients
were right-handed: hand’s dominance was checked by means
of an interview (i.e., we asked the patients and subjects about
their dominance).
Healthy subjects had a mean age (± SD) of 33.2 ± 12.4 years
(range: 24–59 years), with no neurologic or psychiatric diseases.
Patients were diagnosed with clinically definite MS (24)
and had sufficient upper limb motor function to perform the
handgrip task [Medical Research Council (MRC) muscle scale
(rated from 0 to 5) in flexor and extensor hand muscles >
3]. MS patients (mean age ± SD: 36.3 ± 9.5 years; range: 29–
59 years; controls vs. patients: p = 0.42) were enrolled from
the ADEMPTO (The Multiple Sclerosis Patients’ Association
of Toledo, Spain). No significant differences were found for
male/female ratio (p = 0.114). Expanded Disability Status Scale
(EDSS) were used to evaluate neurological impairment and
disability of the MS patients (22). No patients had clinical
relapse in the 3 months preceding the study. All patients had
clinical evidence of pyramidal signs (i.e., hyposthenia, augmented
tendon reflexes, Babinski sign, etc.). Inclusion criteria were:
(a) definite MS diagnosis; (b) disease duration > 3 years;
(c) no cognitive impairment or any substantial decrease in
alertness, language reception, or attention that might interfere
with understanding instructions for motor testing; (d) no
known peripheral nerve pathologies affecting upper limb; (e)
no concomitant neurological conditions, including any history
of epilepsy and significant comorbidities; (f) no apraxia; (g) no
excessive pain in any joint of the arms; (h) no contraindications
to TMS such as metal head implants or cardiac pace-makers;
(i) no advanced liver, kidney, cardiac or pulmonary disease; (j)
no history of significant alcohol or drug abuse; (k) no major
depression or severe psychiatric disorder; (l) practicing physical
activity at least 3 h/week.
Clinical and demographic data of MS patients are described
in Table 1.
All participants, after signing the informed consent, were
interviewed and clinically evaluated by a neurologist to check for
no gross signs of dementia, psychiatric disorders and/or apraxia
and deficit of attention and completed the Fatigue Severity
Scale (FSS). FSS is a self-administered 9-items-questionnaire
that measures the severity of habitual fatigue in different
situations with each item ranging from 1 to 7 (1 indicates
strong disagreement and 7 strong agreement), and with the final
score representing the mean value of the 9 items. Clinically
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DMD Spasticity Pain Fatigue Others
1 SP 25 7 Baclofen Fampidrine
2 RR 15 1
3 SP 24 6.5 Azathioprine Cannabidiol Modafinil
4 RR 20 4.5 Interferon beta-1a Tolterodine
Tartrate,
Escitalopram
5 RR 19 3.5 Dimethyl- fumarate Clonazepam Venlafaxine
6 SP 20 6 Interferon beta-1a Baclofen Amantadine
7 SP 15 6 Fingolimod Cannabidiol Fluoxetine
8 SP 22 8 Baclofen
9 SP 21 6.5 Clonazepam Amantadine
Fampidrine
10 RR 9 2 Dimethylfumarate
11 RR 27 5.5 Interferon beta-1a Fampidrine, Escitalopram
12 RR 5 5.5 Rituximab Pregabalin ASA, Simvastatin,
Trazodone
13 RR 8 4.5
14 SP 5 5 Gabapentin Latanoprost,
Melatonin
15 RR 3 2 Interferon beta-1a
16 RR 6.5 6.5 Interferon beta-1a Baclofen
17 SP 6 6 Azathioprine Baclofen, Cannabidiol Pregabalin Omeprazol
EDSS, Expanded Disability Status Scale; DMD, disease modifying drugs; SP, Secondary Progressive; RR, Relapsing Remitting.
significant fatigue (CSF) was defined as FSS scores greater than or
equal to 4 (29).
Moreover, participants were asked to rate fatigue (fatigue
rating – FR) from 0 (no fatigue) to 10 (extreme fatigue) by means
of a visual analog scale.
MOTOR TASK
To study fatigue state, we used a handgrip task of 2min in which
subjects were asked to squeeze a hand dynamometer to produce
maximal voluntary contraction: subjects were asked to maintain
their maximal strength during the whole duration of the task
and were verbally encouraged to provide maximum contractions.
We a priori decided to evaluate the left hand in control group
while both hands, in two separated sessions, were evaluated in
MS patients.
Handgrip task was performed by using a hand-held
dynamometer (Cibertec SA, Spain) while the subjects were seated
with their shoulder adducted and neutrally rotated, elbow flexed
at 90◦, forearm in neutral position, and wrist between 0 and
30◦ dorsiflexion and between 0 and 15◦ ulnar deviation. During
grasping, subjects were instructed to flex their fingers. Data
were recorded on computer for later analysis using a CED
1401 A/D converter and Spike software (Cambridge Electronic
Design, Cambridge, UK). Maximal handgrip strength (MHS)
was defined as the highest peak torque (Newton, N) obtained
during the 2min handgrip task for each participant. The entire
dynamometer signal (2min) was analyzed by dividing it in 20 s’
blocks (6 blocks in total, namely B1-B6). For each block, the
modulus of the handgrip strength (HS) was quantified and data
were expressed as Newton per seconds (N∗s). Force decay (i.e.,
modulus decay; FD) over the 2min was considered as a marker
of fatigue trait (last 20 s/first 20 s∗100). Modulus is defined as area
over the zero baseline but with all absolute values.
EVALUATION OF PERCEIVED FATIGUE
At the end of each session, all subjects were asked to report
their level of perceived intensity during handgrip using the Borg
Rating of Perceived Exertion Scale (BRPES, range 6–20, where
6 means no exertion at all and 20 means maximal exertion).
Although this is a subjective measure, a person’s exertion rating
may provide a fairly good estimate of physical activity (30).
The total HS modulus of the whole task (THS- N∗s) was also
calculated to quantify the total effort of each subject/patient. The
ratio between the whole task modulus (root squared to reduce
variability) and BRPES were also calculated. This indicates the
effort perception relative to the continuous motor activity.
NEUROPHYSIOLOGICAL STUDY
We aimed to study the effects of an isometric handgrip-fatiguing
task on peripheral and central motor excitability of controls and
MS participants (case-control study design).
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For this reason we used Transcranial Magnetic Stimulation
(TMS) to evaluate central motor excitability and peripheral nerve
stimulation for peripheral motor excitability.
TMS was performed to evaluate central motor excitability
by assessing MEP modulus and central motor conduction time
(CMCT) (see below for details) of both upper limbs in MS
patients and of left upper limb in controls; these parameters were
used as putative markers of corticospinal integrity (31).
Peripheral nerve electrical stimulation (pES) of the ulnar
nerve was used to evaluate peripheral motor excitability by
assessing compoundmuscle action potentials (CMAP) of the first
dorsal interosseous (FDI)muscle (amplitude and latency) and the
F wave latency (see below for details), again for both hands in MS
patients and for left hand in controls.
Central motor excitability and peripheral nerve excitability
were evaluated before and after a 2-min handgrip task both in
MS patients and healthy controls.
Transcranial Magnetic Stimulation
TMS recordings were performed while subjects at rest, with
arm relaxed, elbow flexed at 90 degrees with the forearm
and supinated hand lying on an armrest. Focal TMS of the
hand area of right primary motor cortex (M1) was performed
with a high-power Magstim 200 (Magstim Co., Whitland,
UK), which delivers monophasic pulses. A figure-of-eight
coil (model D70mm Alpha, Magstim Co., Whitland, UK)
was held over the optimum scalp position to elicit motor
responses in the FDI. Intensities were expressed as a percentage
of the maximum output of the stimulator. Throughout all
the experiments, TMS was applied with the handle of the
coil pointing backwards, with the induced current flowing
in a posterior-anterior (PA) direction. The optimum coil
position was defined as the site where TMS consistently
resulted in the largest MEP. Surface electromyography
(EMG) was recorded from the FDI using adhesive electrodes
in a belly-tendon montage. EMG signals were band-pass
filtered (3Hz−3kHz) (Digitimer D360 amplifiers) and single
trials were digitized (sampling rate 10kHz) and recorded
on computer for later analysis using a CED 1401 A/D
converter and Spike software (Cambridge Electronic Design,
Cambridge, UK).
Resting motor threshold (RMT) was defined as the minimum
stimulus intensity that produced a liminal MEP (>50 µV in 50%
of 10 trials) with the tested muscle at rest (32, 33). MEPs were
obtained by recording the responses from the relaxed FDI to 20
single-pulse TMS stimuli (5 s inter-stimulus interval).
Both for patients and controls, MEPs were obtained by
recording the responses from the relaxed FDI to 20 single-pulse
TMS and 20 peripheral nerve stimuli (5 s inter-stimulus interval).
TMS intensity was set at 120% RMT and the same intensity was
used at all-time points after fatiguing task. Modulus of MEPs
(MEPmod) were off-line calculated (mV
∗sec) and utilized as the
value of the dependent variable. Those that exceeded 2 standard
deviations from the session average or that were preceded by clear
EMG activation were manually rejected. MEPmod decrement
after fatiguing task at T1 was also calculated as percentage of
baseline value (T1/T0∗100). We will refer to this variable as
motor system fatigability (MF): the smaller the resulted value the
bigger the MF.
Minimal MEP latency was measured to calculate CMCT
(see below).
Peripheral Electrical Stimulation
The ulnar nerve was stimulated via electrodes placed ∼4 cm
apart along the ulnar side of the wrist. Stimuli were delivered
to the electrodes from a constant current stimulator (pulse
width 200 µs, DS7A; Digitimer, UK) controlled by Spike-2 7.0
software (Cambridge Electronic Design Limited). EMG signals
were obtained with the same parameters than used for TMS and
from the same muscle (FDI).
Electrical RMT (eRMT) was defined as the minimum stimulus
current required to evoke a CMAP of amplitude of approximately
50 µV and this parameter was used to set stimulation intensity
for the experimental session. Then, stimulation intensity was set
at 150% eRMT for peripheral stimulation (34) and then the same
intensity was used at all-time points after the fatiguing task.
Modulus of the CMAPs were off-line calculated (mV∗s) and
utilized as the value of the dependent variable.
Furthermore, only in baseline condition, 10 supramaximal
stimuli were delivered to obtain an F wave (and M wave) to
allow CMCT calculation (see below). To obtain supramaximal
stimulation, the stimulus intensity was increased in 5–10mA to
a level 10% higher than the point where the resultant CMAP did
not increased in modulus.
Central Motor Conduction Time
MEP latency (ms) provides evidence of the integrity of cortico-
spinal tract; particularly the latency of the MEP reflects the
conduction time for neural impulses from the cortex to muscles
(35) and was determined as the minimum time recorded
between TMS shock and MEP onset during the entire baseline
recording block. MEP latency was used to calculate the CMCT
by subtracting the peripheral conduction time (PCT) to the MEP
latency. Peripheral conduction time was calculated using F wave
approach and the following formula: (minimal F wave latency +
Mwave latency-1)/2 (36).
Experimental Design: Effects of Induced
Fatigue on Central and Peripheral
Nervous System
Only in baseline condition we evaluated CMCT, F wave and M
wave to supramaximal stimuli (bilaterally in patients and in the
left hand in controls) for neurophysiological measures and FSS
and FR for the evaluation of fatigue.
On the other hand, we aimed to study the effects of
an isometric fatiguing hand task on peripheral and central
motor excitability of control and MS participants (case-control
study design).
Hence, we recorded 4 blocks of 40 trials each (20 MEPs and
20 CMAPs in a random order), one before the fatiguing task
and 3 after it, as follows: baseline/T0 (before fatiguing task), T1
(immediately after the end of the task), T2 (1min and 40 s after
T1) and T3 (1min and 40 s after T2). At the end of each session,
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all subjects were asked to report their level of perceived intensity
during handgrip using the BRPES.
In all sessions, subjects were seated comfortably and were
instructed to refrain from speaking and to remain awake while in
a calm, relaxed state till the beginning of handgrip task (and after
the end of the handgrip task); the level of muscle contraction was
continuously checked by means an audio-visual EMG feedback.
The EMG background was measured in the 100ms preceding
both TMS and electric pulses to test the level of muscle relaxation
along the experiment. Experimental design is represented
in Figure 1.
STATISTICAL ANALYSIS
Before entering ANOVA data were checked for normality
by means of Kolmogorov-Smirnov test. Data presented are
uncorrected for multiple comparisons.
Healthy and MS Group Comparison.
Male/female ratio was compared using a χ2 test. FSS of both
groups were compared usingMann-Whitney test. Moreover, aχ2
test was used to compare CSF of both groups. Mean age and FR
of both groups were compared using t-test for unpaired data. As
left hand is concerned, CMCT, PCT, RMT, eRMT, MEPmod, and
CMAPmod, of both groups were compared by means of t-test for
unpaired data. To disclose any difference between dominant and
non-dominant side, right hand data (CMCT, PCT, RMT, eRMT,
MEPmodulus, and CMAPmodulus) from MS group were compared
with the MS group left hand data (Table 2) using unpaired t-test.
As five patients were taking drugs to treat fatigue, we compared
the FSS and FR of MS patients receiving anti-fatigue drugs with
those not receiving.
Fatiguing Task
As left hand concerns, MHS and FD of both groups were
compared using an unpaired t-test. Right hand data (MHS and
FD) from MS group were compared with the MS group left
hand data (Table 2) using unpaired t-test. BRPES were compared
between MS patients and healthy subjects (and between hands
in MS group) by means of Mann-Whitney test. FD was
compared between groups (and in MS group between hands).
Dynamometer signal over time was analyzed by dividing it in
6 20-sec-blocks: the modulus of each block was normalized to
the MHS. Normalized data were entered into separate repeated-
measures ANOVA, with BLOCK (B1, B2, B3, B4, B5, B6) as
within-subject’s factors and GROUP (MS, controls) as between-
subject’s factors. Fisher’s Least significant difference (LSD) test
was used for post-hoc comparisons.
Effects of Fatiguing Task on Nervous
System Excitability
Baseline MEP, CMAP and MF of both groups were compared
using unpaired t-test. MEP and CMAP moduli were normalized
to group-average baseline values before entering ANOVA.
Note that this normalization, reduces between-group variability
(imposing mean baseline values equal to 1), while maintaining
the original within-group variability (scaling the variances), thus
respecting the homeostadisticity assumption of the ANOVA (the
variance in baseline is not zero after the normalization) (37).
Afterwards, normalized values were entered into two separate
repeated measures ANOVAs (GROUP x TIME) for MEP and
CMAP. LSD significant difference test was used for post-hoc
comparisons. Right hand data from MS group were compared
with the MS group left hand data. All results were considered
significant at p < 0.05.
In order to exclude the effects of changes in peripheral
system, MEP data were normalized to the baseline Maximal
M-wave (CMAP data) and these values were entered into two
separate repeatedmeasures ANOVAs (GROUP x TIME) forMEP
and CMAP.
Correlation Analysis
Both in patients and controls, we performed Spearman test
between FSS and FR vs. maximal handgrip strength (MHS) and
force decay (FD), between BRPES vs. FD and MF to explore the
influence of fatigue trait on the handgrip task and the influence of
fatigue state vs. force decay and the change in MEPmod recorded
after the task.
Only for MS patients, Spearman correlations between EDSS
vs. FSS and FR and between FSS and FR vs. CMCT were
performed to evaluate the impact of general fatigue on
disability and the impact of corticospinal function on fatigue
trait, respectively.
RESULTS
All the participants tolerated the whole experimental procedure
and none experienced TMS related side effects. One MS
participant had no recordable MEPs in the left FDI muscle
and this side was excluded from final analysis of the
neurophysiological variables. Kolmogorov-Smirnov test showed
that data had normal distribution.
Data are summarized in Table 2.
Healthy and MS Group Comparison:
Baseline Condition
FSS scores, FR, CMCT, RMT, and MEPmod were significantly
different between groups (Table 2). Moreover, the CMAPmod
was smaller in MS group (Table 2). Clinically significant fatigue
was present in 11/17MS patients and in 3/16 of healthy
subjects (p < 0.05). On the other hand, PCT, and eRMT
were similar in both groups (Table 2). In MS group, no
differences were observed between left and right hand (Table 2).
No differences were observed between the MS patients taking
and not taking anti-fatigue drugs in FSS, Fatigue Rating and
Borg scale of both hands (all p > 0.5). Figure 2 shows
single MEP and CMAP in a representative control and a
representative patient.
Fatiguing Task
Maximal Handgrip Strength was significantly lower in MS
group than in the control group, while force decay and
Borg Scale were similar in both groups. Recordings from a
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FIGURE 1 | Schematic representation of the experimental setup.










MS left vs. right
CLINICAL VARIABLES
N 16 17
EDSS 5.06 ± 1.93
FSS 2.98 ± 0.91 4.67 ± 1.75 0.0014*** ————– ————–
CSF (FSS≥4) n 3 11 0.0076** ————– ————–
FR 1.46 ± 1.22 4.92 ± 2.45 <0.0001* ————– ————–
NEUROPHYSIOLOGICAL VARIABLES
N 16 16 17
CMCT (ms) 4.6 ± 1.0 7.7 ± 4.1 0.0093* 8.7 ± 3.8 0.4798*
PCT (ms) 15.2 ± 0.7 15.4 ± 0.5 0.4295* 15.5 ± 0.7 0.6311*
RMT (% MSO) 44.9 ± 9.9 62.8 ± 24.7 0.0139* 68.8 ± 22.7 0.5239*
eRMT (mA) 12.46 ± 3.70 12.17 ± 3.34 0.8134* 12.25 ± 3.37 0.9143*
MEP (mV*s) 120%RMT 0.0129 ± 0.0070 0.0052 ± 0.0032 0.0007* 0.0077 ± 0.0063 0.1479*
CMAP (mV*s) 150%eRMT 0.0237 ± 0.0150 0.0141 ± 0.0030 0.0241* 0.0122 ± 0.0034 0.0999*
MF (T1/T0) (%) 72.916 ± 38.3 113.843 ± 51.1 0.0161* 98.102 ± 33.5 0.3299*
MF (T2/T0) (%) 84.856 ± 29.51 107.90 ± 40.42 0.0763* 105.493 ± 39.4 0.8685*
MOTOR TASK AND PERCEIVED FATIGUE
N 16 16 17
MHS (N) 239.485 ± 139.742 107.65 ± 43.898 0.0021* 125.253 ± 46.487 0.110*
FD (%) 73.562 ± 17.409 81.914 ± 29.48 0.3388* 80.216 ± 20.08 0.897*
BRPES 14.6 ± 1.7 13.7 ± 2.2 0.196*** 13.6 ± 1.8 0.973***
POWER (N*s) 15492.26 ± 9832.35 5641.26 ± 3096.91 0.001* 7057.76 ± 3379.89 0.153*
POWER/BRPES 0.0013 ± 0.0008 0.013 ± 0.041 0.005* 0.0023 ± 0.001 0.222*
*, T test; **, X2; ***, Mann-Whitney.
EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; CSF, Clinically Significant Fatigue; FR, Fatigue Rating; CMCT, Central Motor Conduction Time; PCT, Peripheral
Conduction Time; RMT, Resting Motor Threshold; eRMT, electrical Resting Motor Threshold; MEP, Motor Evoked Potential; CMAP, Compound Motor Action Potential; MF, Motor System
Fatigability; MHS, maximal handgrip strength; FD, Force decay; BRPES, Borg Rating of Perceived Exertion Scale. Bold values indicate significant difference between groups.
representative control and a representative patient are shown
in Figure 3.
When comparing force decay and Borg Scale in dominant
and non-dominant side in MS patients, no differences
were found (Table 2). In few words, both patients and
controls evaluated the muscular effort produced during
handgrip as “somewhat hard.” Moreover, no differences were
observed in Borg Scale when comparing left to right hand in
patients (Table 2).
We compared force decay between groups (and in MS
group between hands). Normalized data showed a progressive,
significant decrement of the modulus over time [ANOVA, TIME:
F(5, 150) = 68.489, p < 0.001) in both groups without any
significant difference between MS and control groups [ANOVA,
TIME x GROUP: F(5, 150) = 1.125, p= 0.35]. Similar results were
obtained when left and right hand were compared in MS group
[ANOVA, TIME: F(5, 155) = 100.09, p < 0.001; TIME x HAND:
F(5, 155) = 1.35, p= 0.25].
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FIGURE 2 | Recordings of Motor Evoked Potentials and Compound Motor Action Potentials in a representative control and a representative patient.
FIGURE 3 | Recordings of electromyography background and handgrip task in a representative control and a representative patient.
Effects of Fatiguing Task on Nervous
System Excitability
The effects of fatiguing task on normalized MEPmod to baseline
were significantly different between the two groups [ANOVA,
TIME x GROUP: F (3, 90) = 2.729, p = 0.048]. Particularly,
normalized MEPmod significantly decreased immediately after
the fatiguing task (Fisher’s LSD: T0 vs. T1; p = 0.0019) in the
control group and then slightly recovered (Fisher’s LSD: T0 vs.
T2; p = 0.201 T0 vs. T3; p = 0.545). Particularly, immediately
after the end of fatiguing task, MEP modulus was reduced with
27% in the control group while no changes were observed in
the MS group over time (Figure 4). MF was different between
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MS and control groups (T1/T0, p = 0.0161; T2/T0, p = 0.0763]
with bigger MF in controls than in patients (Table 2). No
differences were observed between left and right hands in MS
group (Table 2).
The effects of fatiguing task on normalized MEPmod to
baseline maximal M-wave were significantly different between
the two groups [ANOVA, TIME x GROUP: F (3, 90) = 5.123, p =
0.002]. Particularly, normalized MEPmod significantly decreased
after the fatiguing task (Fisher’s LSD: T0 vs. T1, p < 0.001; T0 vs.
T2, p = 0.018) in the control group and then slightly recovered
(Fisher’s LSD: T0 vs. T3, p= 0.268).
Furthermore, significant differences were observed after
fatiguing task on the normalized CMAPmod to baseline [ANOVA,
TIME x GROUP: F (3, 90) = 3.701, p = 0.015]. More in details,
normalized CMAPmod significantly decreased immediately after
the fatiguing task (Fisher’s LSD: T0 vs. T1; p = 0.0038 T0 vs. T2;
p = 0.0005 T0 vs. T3; p = 0.0069] in the control group whereas
no changes were observed in the MS group over time.
The effects of fatiguing task on normalized CMAPmod to
baseline maximal M-wave were significantly different between
the two groups [ANOVA, TIME x GROUP: F (3, 90) = 2.943, p =
0.037]. Particularly, normalized MEPmod significantly decreased
after the fatiguing task (Fisher’s LSD: T0 vs. T1, p = 0.008; T0 vs.
T2, p= 0.001; T0 vs. T3, p= 0.014) in the control group whereas
no changes were found in the MS group over time.
The EMG background was similar in both groups over time
[ANOVA: TIME: F (3, 90) = 66.54, p < 0.001; TIME x GROUP:
F (3, 30) = 0.5692, p =0.6367]. The EMG background registered
over the FDI significantly increase in the first time point after the
fatiguing task in both groups (Fisher’s LSD: T0 vs. T1; p < 0.001
in healthy subjects and T0 vs. T1; p < 0.001 in MS patients).
Correlation Analysis
Positive correlation was found between FSS and force decay
(Spearman: rho = 0.544, p = 0.029), FR and FD (Spearman:
rho = 0.828, p < 0.001), and a negative correlation was found
between Borg scale and force decay (Spearman: rho = −0.604, p
= 0.013) just in healthy subjects.
Correlation analysis results are summarized in Table 3.
FIGURE 4 | Normalized Motor Evoked Potentials in healthy subjects and MS
patients at baseline and after fatiguing task. Error bars are standard deviations.
*p < 0.05.
DISCUSSION
Our data confirmed the expected baseline differences between
MS patients and controls: particularly we found a reduced
CMAP and MEP modulus and an increased RMT in MS patients
when compared to controls. Our data fits well with those of
previous studies demonstrating an impairment of corticospinal
tract in MS (35, 36, 38, 39). On the other hand, we found a
reduction of baseline CMAP modulus in MS patients. Although
MS affects CNS, the existence of a subclinical involvement
of the peripheral nervous system, thought to be associated to
MS or induced by muscular non-use or disability in general,
was previously demonstrated (40). In this scenario, we cannot
exclude that MEP modulus reduction depends on the subclinical
impairment of peripheral nerve targeting FDI. On the other
hand, the absence of an impairment of the latency excludes gross
peripheral conduction abnormalities and severe axonal damage
in the studied peripheral nerve (see also study limitations).
Furthermore, the reduction of MEP modulus in MS patients
could be drug-dependent since the patients included in the
present study were taking several CNS active drugs, as shown
in Table 1. However, when the pharmacological treatments of
our patients was reviewed, it could be shown that 2 patients
were taking clonazepam (a GABA-A agonist), 5 patients were
taking baclofen (a GABA-B agonist), 2 patients were taking
pregabaline, 1 patient gabapentine, 2 patients amantadine, 1
patient modafinil, 3 patients cannabidiol, and only 4 patients
were taking anti-depressant drugs (1 Venlafaxine 1 Fluoxetine
and 2 Escitalopram). In this context, just GABA-A agonist
could affect motor threshold (i.e., increasing it) and MEP
amplitude (i.e., reducing it) whereas the other mentioned
drugs did not substantially reduce motor cortex excitability as
reported by Ziemann (41). When we take into account these
observations we can suppose that the reduction of motor cortex
excitability in the MS patients group was not primarily due to a
pharmacological effect.
MS patients showed clinically significant fatigue in 2/3 of
the patients (11/17), even considering that a few patients were
receiving anti-fatigue drugs. Only four patients were taking anti-
depressant drugs and none of the patients or subjects referred
significant mood disorders during baseline clinical interview. It is
demonstrated thatmood as well as sleep disorders are common in
MS and could participate in the perception of fatigue in daily live
activities (42). We did not formally screened for sleep disorders,
which in any case were not reported by the participants in the
general interview.
As expected, patients presented diminishedmaximal handgrip
strength and corticospinal dysfunction (prolonged CMCT).
Moreover, there was a tendency to negative correlation between
these latter parameters (the longer the CMCT the less the
maximal handgrip strength). On the other hand, fatigue state
shown by the motor decay that subjects experienced during
the isometric fatiguing task was similar in both MS patients
and healthy controls (of course MS patients started the task
with much less strength). Both patients and controls had also
similar perceived fatigue state of the executed task, but whilst
in controls there was a correlation between the force decay and
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TABLE 3 | Correlational analysis: Evaluation of the influence of habitual fatigue
level on the handgrip task and the influence of perceived task-related fatigue vs.
FD and MF and the impact of general fatigue on disability as well as the impact of
corticospinal function on general fatigue.
Correlation MS patients Healthy subjects
FSS and MHS Left hand Rho = 0.059, p = 0.827
Rho = −0.017, p = 0.948
Right hand
Rho = −0.020 p = 0.937
FR and MHS Left hand Rho = 0.273, p = 0.307
Rho = 0.140, p = 0.606
Right hand
Rho = 0.153, p = 0.557
FSS and FD Left hand Rho = 0.544, p = 0.029
Rho = 0.054, p = 0.841
Right hand
Rho = −0.060, p = 0.819
FR and FD Left hand Rho = 0.828, p<0.001
Rho = 0.078, p = 0.774
Right hand
Rho = −0.124, p = 0.636
BRPES and FD Left hand Rho = -0.604, p = 0.013
Rho = 0.317, p = 0.231
Right hand
Rho = −0.059, p = 0.823
MF (T1/T0*100)
and BRPES
Left hand Rho = -0.377, p = 0.712
Rho = 0.131, p = 0.628
Right hand
Rho = −0.362, p = 0.152
MF (T2/T0*100)
and BRPES
Left hand Rho = -0.009, p = 0.973
Rho = 0.399, p = 0.126
Right hand
Rho = −0.190, p = 0.464
EDSS and FSS Rho = 0.164, p = 0.528
EDSS and FR Rho = 0.219, p = 0.398
FSS and CMCT Left hand
Rho = 0.384, p = 0.142
Right hand
Rho = 0.297, p = 0.247
FR and CMCT Left hand
Rho = 0.225, p = 0.402
Right hand




Rho = −0.26,p = 0.33;
Right hand
Rho = −0.37, p = 0.14
Spearman test was conducted for correlational analysis.
EDSS, Expanded Disability Status Scale; FSS, Fatigue Severity Scale; CSF, Clinically
Significant Fatigue; FR, Fatigue Rating; CMCT, Central Motor Conduction Time; MF,
Motor System Fatigability; MHS, maximal handgrip strength; FD, Force decay; BRPES,
Borg Rating of Perceived Exertion Scale. Bold values indicate significant difference
between groups.
both for general fatigue trait (scores FSS and FR) and fatigue state
(Borg scale), in the MS group this correlation was not present.
In other words, fatigue trait and fatigue state in MS patients
are independent from handgrip strength as well as fatigue state
is independent from fatigue trait. Moreover, FSS and force
decay were independent from the corticospinal tract dysfunction
(CMCT). As FSS concerns, we have to take into account that is
a multidimensional scale used for a gross evaluation of fatigue in
daily life, so its relationship with the corticospinal tract can be
tiny. Furthermore, lack of correlation between corticospinal tract
dysfunction and force decay suggests that force decay induced by
an isometric task does not depend on corticospinal dysfunction
in MS. Differently from control group, we were unable to
detect clear MF (by TMS after the handgrip task) or a clear
reduction in peripheral nerve excitability in MS. Previous studies
reported a lower decay in cortical excitability (43) or an increase
(i.e., compensatory) in central motor drive in MS patients (23,
44) even if these authors reported also a similar reduction
of peripheral nerve excitability in MS and controls. This
discrepancy was probably due to the normality of CMCT in MS
patients found in previous studies (43), while patients included
in our study were characterized by CMCT alteration. This
suggests that in our MS patients, the dysfunction in corticospinal
connection (i.e., increased CMCT), reduced the torque realized
during the task (MHS lower than controls), impeded, together
with the subclinical alteration in peripheral nervous system
demonstrated in patients, a reduction in peripheral nerve
excitability and induced a compensatory increase in motor cortex
excitability, that prevented MEP reduction after fatiguing task.
Following correction, taking in consideration the real total
effort performed by the subjects (THS/BRPES), we can note that
the perceived fatigue is much more in the MS group. Based
on these data, a number of considerations could be suggested
with proper caution: (1) Fatigue trait does not depend on
corticospinal dysfunction in MS; (2) force decay induced by an
isometric task does not depend on corticospinal dysfunction in
MS; (3) maximal handgrip strength depends on corticospinal
dysfunction in MS; (4) Perceived fatigue in MS is higher than in
controls (similar perceived fatigue with much less THS); (5) MEP
and CMAP changes after 2-min isometric fatiguing task are not
able to measure fatigue in MS, probably due to a central motor
drive compensation.
CENTRAL FATIGUE GENERATION
MEP amplitude indirectly measures the descending corticospinal
drive and, in healthy subjects, fatigue affects this descending
activity (32).
In our experiment, healthy subjects showed a reduction in
MEP modulus in line with other previous results that report an
increase during the fatiguing task and a post-fatigue reduction
in MEP amplitude (17). However, as elegantly described by
Gandevia, MEP amplitude increased after 2min of MVC just
for the first 30 s and after 60 s began to decrease (20), so it is
not surprising that our data demonstrated a MEP reduction in
healthy subjects in the first minutes recording block as facilitation
prevails just for the first 30 s. The post-exercise facilitation is
probably due to the difficulty to keep themuscle fully relaxed after
the fatiguing task (20). Our data on EMG background confirm
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the reduced relaxation immediately after the task. On the other
hand, in the first block after the fatiguing task we observed similar
values of the EMG background for controls and MS subjects,
suggesting that the difference in MEP changes could not be
explained by different muscle relaxation capacity between the
two groups.
This point could further suggest that controls show a
reduction in corticospinal output, after fatiguing task, while MS
patients do not. In this context, it could be considered that fatigue
state in MS patients also depends on connectivity changes in
motor and non-motor basal ganglia, including motivation and
reward circuits (13, 45, 46) and could be also due to adaptive
changes that take place in MS pathological process along with the
whole duration of the illness, related to clinical and subclinical
neuropsychiatric changes, as well as depression and cognitive
impairment (47, 48). Furthermore, fatigue-induced cortical
hyperexcitability was already described in MS patients (23, 44).
The two phenomena could indicate a cortical reorganization
that might serve to compensate for progressive tissue damage
by MS (49) and could contribute to fatigue pathophysiology in
multiple sclerosis (i.e., the more the reorganization the more
central fatigue).
LIMITATIONS OF THE STUDY
It is important to note that the present study presents some
limitations that could affect result interpretation.
We recruited the MS study participants in a consecutive
manner from a patient association, and for this reason the cohort
of the MS group was not homogeneous. Patients were taking
different disease-modifying drugs and symptomatic medications
that may affect our findings. Unfortunately, due to the limited
number of patients included in the study, we could not perform
further analysis to differentiate the effects of each drug on our
results. For example, it should be considered that interferon could
affect fatigue itself, directly but also indirectly, by means of a
drug-induced worsening of sleep duration, quality, and stability
(50). Moreover, we did not formally screen patients for sleep
disorders, so that we cannot quantify and evaluate the sleep-
induced effects on fatigue.
Another limitation is the lack of further neurophysiological
work-up in our study: particularly we did not evaluate other
TMS protocols that can provide information about GABA-A and
GABA-B circuits or plasticity. However, our main objective was
to observe and study the changes in fatigue induced by a handgrip
and its relationship with corticospinal tract, so we considered
that paired-pulse TMS and protocols to evaluate plasticity were
beyond the main objective of the present study.
Furthermore, we did not analyze the neuroradiological
findings at the moment of the study (or close by the study).
Similarly, we do not have a formal clinical neurophysiological
assessment of the peripheral nervous system (motor and
sensory nerve conduction studies, F-waves, H-reflexes, and
needle EMG). Obviously, the lack of these kinds of information
prevented the execution of further correlations’ analysis that
could have been provided further relevant details about the
phenomena observed.
CONCLUSIONS
Since MS patients and healthy subjects present important
neurophysiological differences in baseline conditions, also fatigue
generation mechanisms were different between the two groups.
In healthy subjects, isometric fatiguing task induces a central
fatigue that involves corticospinal functions as demonstrated by
MEP reduction and confirmed by analyzing data normalized
to M-wave excluding by this way a possible effect over the
peripheral nervous system. In MS patients, the pathogenesis of
fatigue seems not driven by the mechanisms directly related to
corticospinal function (that characterize fatigue in controls) but
seems probably due to other “central abnormalities” upstream to
primary motor cortex (11).
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